Fluorescence based T-type channel assay
View Patent ↗A fluorescence based assay for compounds that modulate T-type calcium ion channels and that can be adapted to high throughput screening formats. Modulators of T-type channels are useful to correct functional abnormalities. These abnormalities are associated with epilepsy, pain, schizophrenia, depression, anxiety, cardiac arrhythmia, hypertension, certain types of cancer, diabetes, infertility, sexual dysfunction and other undesirable conditions.
1. A method to detect the activation of T-type calcium ion channels, which method comprises
treating cells that express at least the α 1 subunit of a T-type calcium ion channel with sufficient potassium ion to activate said T-type channel, and
measuring the fluorescence emitted by such cells,
wherein the cells have been modified to contain a fluorophore having an intensity of emission that changes in the presence of calcium ion, and
wherein said cells have been treated, prior to treating with potassium ion to activate said T-type channel, with a monovalent cation-selective pore-forming substance that permits the influx and efflux of singly charged cations so as to create a cation-selective pore in the presence of a solution comprising at least one osmolality balancing component that does not permeate said pore,
wherein said solution is an isotonic solution prepared by substituting said at least one osmolality balancing component for sodium ions,
wherein enhancement of the intensity of fluorescence emission indicates the activation of said T-type calcium ion channels.
2. The method of claim 1 , wherein the intensity of emission of said fluorophore is enhanced in the presence of calcium ion.
3. The method of claim 1 , wherein the monovalent cation selective pore-forming substance is selected from the group consisting of gramicidin, artificial ion channels, and bacterial toxins.
4. The method of claim 1 , wherein the osmolality balancing component comprises one or more of N-methyl-D-Glucamine (NMDG), choline, tris [hydroxymethyl] aminomethane (TRIS) and tetra-ethyl-ammonium (TEA).
5. A method to detect the activation of T-type calcium ion channels, which method comprises
(a) treating cells that express at least the α 1 subunit of a T-type calcium ion channel with a monovalent cation-selective pore-forming substance other than a potassium-selective ion channel so as to create a cation-selective pore in the presence of a solution comprising at least one osmolality balancing component that does not permeate said pore,
wherein said solution is an isotonic solution prepared by substituting said at least one osmolality balancing component for sodium ions, and
whereby the membrane potential of said cells becomes sufficiently negative to convert inactivated T-type channels to the resting state; followed by
(b) increasing the potassium ion concentration external to said cells so as to depolarize said cell membranes sufficiently to activate the T-type channels; and
(c) measuring the fluorescence emitted by the cells, wherein the cells have been modified to contain a fluorophore having an intensity of emission that changes in the presence of calcium ion,
wherein enhancement of the intensity of fluorescence emission indicates activation of said T-type calcium ion channels.
6. The method of claim 5 , wherein the intensity of emission of said fluorophore is enhanced in the presence of calcium ion.
7. The method of claim 5 , wherein the monovalent cation selective pore-forming substance is selected from the group consisting of gramicidin, artificial ion channels, and bacterial toxins.
8. The method of claim 5 , wherein the osmolality balancing component comprises one or more of N-methyl-D-Glucamine (NMDG), choline, tris [hydroxymethyl] aminomethane (TRIS) and tetra-ethyl-ammonium (TEA).
9. The method of claim 7 , wherein the cation selective pore-forming substance is gramicidin.
10. The method of claim 7 , wherein the monovalent cation-selective pore-forming substance is an artificial ion channel comprising a cyclic peptide containing unnatural amino acids.
11. The method of claim 7 , wherein the bacterial toxin is Clostridium perfringens beta toxin.
12. The method of claim 7 , wherein the osmolality balancing component comprises one or more of N-methyl-D-Glucamine (NMDG), choline, tris [hydroxymethyl]aminomethane (TRIS) and tetra-ethyl-ammonium (TEA).
13. The method of claim 12 , wherein the osmolality balancing component is NMDG or choline.
14. The method of claim 12 , wherein the osmolality balancing component is choline.
15. A method to detect the activation of T-type calcium ion channels, which method comprises
(a) providing cells that express at least the α 1 subunit of a T-type calcium ion channel and which have been recombinantly modified to coexpress a potassium-selective ion channel, and wherein said cells have been modified to contain a fluorophore having an intensity of emission that changes in the presence of calcium ion;
(b) maintaining the potassium ion concentration external to said cells at a level so as to obtain a negative membrane potential sufficient to convert inactivated T-type channels to the resting state; followed by
(c) increasing the potassium ion concentration external to the cells to depolarize the cell membranes sufficiently to activate said T-type calcium ion channels; and
(d) measuring the excitation fluorescence emitted by the fluorophore in said cells; wherein enhancement of the intensity of fluorescence emission indicates activation of the T-type calcium ion channels.
16. The method of claim 15 , wherein the potassium-selective ion channel is IRK-1, TASK-1, TASK-3, TREK-1, TREK-2 or TRAAK.
17. The method of claim 15 , wherein the intensity of the excitation fluorescence of said fluorophore is enhanced in the presence of calcium ion.
18. The method of claim 16 , wherein the intensity of the excitation fluorescence of said fluorophore is enhanced in the presence of calcium ion.